
Personalis Inc. is a biotechnology company focused on advanced cancer genomics and precision oncology. Personalis develops and markets genomic tests and sequencing services that help healthcare providers, pharmaceutical companies, biopharma partners, universities, and government organizations analyze tumor and immune-system signals. Its current offerings include liquid biopsy and molecular profiling solutions designed to detect minimal residual disease, monitor recurrence, and support therapy selection, along with sequencing and data analysis services for population-scale research programs. The company also provides platforms and assays used in immuno-oncology and personalized cancer vaccine development. Personalis serves customers primarily in the United States and Europe, with additional international reach through research and clinical applications. Headquartered in Fremont, California, Personalis plays an important role in translating complex genomic data into actionable insights for cancer research and patient management.
www.personalis.com